Myelodysplastic syndrome with cryptic 5q deletions in young male patients showing sustained response to lenalidomide

Key Points

• The aim is to investigate the response to lenalidomide in young male patients with myelodysplastic syndrome and cryptic 5q deletions.
• Provided treatment with lenalidomide
• Monitored hematologic responses
• Conducted cytogenetic analyses to identify 5q deletions
• Patients showed significant hematologic response to lenalidomide treatment
• Cryptic 5q deletions were confirmed in young male patients
• Response was sustained over a defined treatment duration